Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -247.86% | 65.65% | -15.90% | -9.01% | -3.96% |
| Total Depreciation and Amortization | -162.30% | 439.82% | -3.42% | 117.28% | -172.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 61.06% | 3.43% | 17.34% | 20.98% | 29.99% |
| Change in Net Operating Assets | 234.84% | -480.26% | 214.51% | -3,111.96% | -84.50% |
| Cash from Operations | 71.93% | -12.26% | 18.65% | -26.35% | -8.31% |
| Capital Expenditure | -88.98% | -202.38% | 51.16% | 24.56% | 61.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -368.76% | 66.58% | -24.35% | 259.47% | 25.57% |
| Cash from Investing | -369.22% | 66.51% | -24.33% | 259.04% | 25.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,024.33% | 1,348.43% | -91.89% | -74.43% | -84.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 15,074.16% | -- | 100.00% | 84.20% | 91.35% |
| Cash from Financing | 3,638.68% | 1,321.07% | -91.71% | -74.07% | -85.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.32% | 4,618.03% | -93.33% | 116.50% | -208.71% |